2005 Frontiers in Anesthesia Research Award $500,000
Michael Zaugg, MD, MBA, FRCPC
During Award Period
University of Zurich
Department of Anesthesiology and Pain Medicine
University of Alberta
Edmonton, Alberta, Canada
Dr. Zaugg’s Research
Functional Genomics of Anesthetic Protection in Human Myocardium
Propofol (Diprivan®) and Intralipid Exacerbate Insulin Resistance in Type-2 Diabetic Hearts by Impairing GLUT4 Trafficking.
Lou PH, Lucchinetti E, Zhang L, Affolter A, Gandhi M, Zhakupova A, Hersberger M, Hornemann T, Clanachan AS, Zaugg M.
The IV anesthetic, propofol, when administered as fat emulsion-based formulation (Diprivan) promotes insulin resistance, but the direct effects of propofol and its solvent, Intralipid, on cardiac insulin resistance are unknown.
Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat.
Warren BE, Lou PH, Lucchinetti E, Zhang L, Clanachan AS, Affolter A, Hersberger M, Zaugg M, Lemieux H.
Although evidence that type 2 diabetes mellitus (T2DM) is accompanied by mitochondrial dysfunction in skeletal muscle has been accumulating, a causal link between mitochondrial dysfunction and the pathogenesis of the disease remains unclear. Our study focuses on…
Read Dr. Zaugg’s recent publications and articles.